+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)
Non-steroidal Anti-inflammatory Drugs Market - Global Forecast 2026-2032- Product Image
Non-steroidal Anti-inflammatory Drugs Market - Global Forecast 2026-2032- Product Image
New

Non-steroidal Anti-inflammatory Drugs Market - Global Forecast 2026-2032

  • PDF Icon

    Report

  • 190 Pages
  • January 2026
  • Region: Global
  • 360iResearch™
  • ID: 5666179
1h Free Analyst Time
Description Jump to:
1h Free Analyst Time

Speak directly to the analyst to clarify any post sales queries you may have.

The Non-steroidal Anti-inflammatory Drugs (NSAIDs) market is evolving rapidly, shaped by new therapeutic needs, regulatory dynamics, and commercial strategies. Senior decision-makers must understand how these forces converge to drive both opportunity and complexity across global healthcare supply chains and commercial models.

Market Snapshot

The Non-steroidal Anti-inflammatory Drugs market is projected to grow from USD 24.62 billion in 2025 to USD 26.22 billion in 2026, reaching USD 38.81 billion by 2032, driven by a CAGR of 6.71%. NSAIDs maintain a critical role in pain and inflammation management for both medical professionals and consumers, as market factors such as evolving clinical practice, regulatory oversight, and patient preferences continue to shift industry dynamics.

Scope & Segmentation

  • Distribution Channels: Includes Over The Counter and Prescription pathways.
  • Routes of Administration: Covers Oral, Parenteral, and Topical therapies.
  • Drug Classes: Analyzes COX-2 Inhibitors and Nonselective COX Inhibitors for insight into safety and prescriber behaviors.
  • Formulation Types: Studies Capsules, Creams, Gels, Powders, Suspensions, Tablets, and Transdermal Patches, focusing on delivery innovations and patient adherence.
  • End User Settings: Addresses niches including Hospital Pharmacy, Online Pharmacy, and Retail Pharmacy.
  • Geographic Regions: Provides analysis for Americas, Europe, Middle East & Africa, and Asia-Pacific, each with distinct regulatory, commercial, and manufacturing considerations.
  • Technology Trends: Examines the influence of topical and transdermal advancements, digital channel expansion, and supply chain innovations.

Key Takeaways

  • Therapeutic positioning is shifting as clinicians balance benefit-risk profiles, especially for patients with additional health risk factors.
  • Formulation innovation is expanding the application of localized and transdermal NSAID therapies, addressing the demand for improved safety and tolerability.
  • Digital channels and telehealth influence both consumer purchasing and prescription fulfillment, requiring new engagement models from manufacturers.
  • Evolving safety requirements and real-world evidence have become central to capturing prescriber trust and payer support for product differentiation.
  • Segment-specific strategies are essential, as requirements diverge across OTC and prescription channels, oral versus topical administration, and institutional versus retail pharmacy environments.
  • Supply chain resilience is now a core competitive factor, particularly for firms navigating regulatory, tariff, or geopolitical disruptions.

Tariff Impact

Recent United States tariff changes through 2025 have required manufacturers to reassess sourcing and distribution strategies. These cost pressures have increased the importance of multi-sourcing, inventory management, and regional contract partnerships. Companies with vertically integrated supply chains have demonstrated greater agility, while others have faced sharper margin pressures and more complex compliance demands across procurement, regulatory affairs, and trade operations.

Methodology & Data Sources

This research leverages primary interviews with clinicians, procurement leaders, and commercial executives, complemented by secondary analysis of regulatory filings, clinical literature, manufacturing databases, and patent records. Rigorous data triangulation, scenario analysis, and cross-functional validation ensure comprehensive, actionable insights tailored to the complexities of the NSAIDs market.

Why This Report Matters

  • Enables senior leaders to design resilient commercial and supply strategies adapted to regulatory, technological, and market shifts.
  • Identifies actionable segmentation opportunities and risk mitigation tactics for sustained growth and competitive positioning.
  • Supports pragmatic investment and resource allocation decisions grounded in robust clinical and commercial evidence.

Conclusion

To lead effectively in the NSAIDs landscape, it is essential to integrate evidence-driven product strategies, agile manufacturing, and tailored channel execution. Strong cross-functional collaboration ensures operational resilience as the market continues to evolve in complexity and scope.

 

Additional Product Information:

  • Purchase of this report includes 1 year online access with quarterly updates.
  • This report can be updated on request. Please contact our Customer Experience team using the Ask a Question widget on our website.

Table of Contents

1. Preface
1.1. Objectives of the Study
1.2. Market Definition
1.3. Market Segmentation & Coverage
1.4. Years Considered for the Study
1.5. Currency Considered for the Study
1.6. Language Considered for the Study
1.7. Key Stakeholders
2. Research Methodology
2.1. Introduction
2.2. Research Design
2.2.1. Primary Research
2.2.2. Secondary Research
2.3. Research Framework
2.3.1. Qualitative Analysis
2.3.2. Quantitative Analysis
2.4. Market Size Estimation
2.4.1. Top-Down Approach
2.4.2. Bottom-Up Approach
2.5. Data Triangulation
2.6. Research Outcomes
2.7. Research Assumptions
2.8. Research Limitations
3. Executive Summary
3.1. Introduction
3.2. CXO Perspective
3.3. Market Size & Growth Trends
3.4. Market Share Analysis, 2025
3.5. FPNV Positioning Matrix, 2025
3.6. New Revenue Opportunities
3.7. Next-Generation Business Models
3.8. Industry Roadmap
4. Market Overview
4.1. Introduction
4.2. Industry Ecosystem & Value Chain Analysis
4.2.1. Supply-Side Analysis
4.2.2. Demand-Side Analysis
4.2.3. Stakeholder Analysis
4.3. Porter’s Five Forces Analysis
4.4. PESTLE Analysis
4.5. Market Outlook
4.5.1. Near-Term Market Outlook (0-2 Years)
4.5.2. Medium-Term Market Outlook (3-5 Years)
4.5.3. Long-Term Market Outlook (5-10 Years)
4.6. Go-to-Market Strategy
5. Market Insights
5.1. Consumer Insights & End-User Perspective
5.2. Consumer Experience Benchmarking
5.3. Opportunity Mapping
5.4. Distribution Channel Analysis
5.5. Pricing Trend Analysis
5.6. Regulatory Compliance & Standards Framework
5.7. ESG & Sustainability Analysis
5.8. Disruption & Risk Scenarios
5.9. Return on Investment & Cost-Benefit Analysis
6. Cumulative Impact of United States Tariffs 2025
7. Cumulative Impact of Artificial Intelligence 2025
8. Non-steroidal Anti-inflammatory Drugs Market, by Drug Class
8.1. Acetic Acid Derivatives
8.1.1. Diclofenac
8.1.2. Ketorolac
8.2. Fenamates
8.2.1. Flufenamic Acid
8.2.2. Mefenamic Acid
8.3. Oxicams
8.3.1. Piroxicam
8.3.2. Tenoxicam
8.4. Propionic Acid Derivatives
8.4.1. Flurbiprofen
8.4.2. Ibuprofen
8.4.3. Ketoprofen
8.4.4. Naproxen
8.5. Salicylates
8.5.1. Aspirin
8.5.2. Diflunisal
8.6. Selective COX-2 Inhibitors (Coxibs)
8.6.1. Celecoxib
8.6.2. Etoricoxib
9. Non-steroidal Anti-inflammatory Drugs Market, by Formulation
9.1. Capsules
9.2. Creams/Gels
9.3. Powders
9.4. Tablets
10. Non-steroidal Anti-inflammatory Drugs Market, by Route Of Administration
10.1. Oral
10.2. Parenteral
10.3. Topical
11. Non-steroidal Anti-inflammatory Drugs Market, by Prescription Status
11.1. Over-The-Counter
11.2. Prescription Only
12. Non-steroidal Anti-inflammatory Drugs Market, by Release Type
12.1. Immediate-Release
12.2. Modified-Release
12.2.1. Controlled-Release
12.2.2. Delayed-Release/Enteric-Coated
12.2.3. Extended-Release
13. Non-steroidal Anti-inflammatory Drugs Market, by Patient Group
13.1. Adults
13.2. Geriatric
13.3. Pediatric
14. Non-steroidal Anti-inflammatory Drugs Market, by Indication
14.1. Acute Pain
14.1.1. Dental Pain
14.1.2. Musculoskeletal Injury (Sprain/Strain)
14.1.3. Postoperative Pain
14.2. Ankylosing Spondylitis
14.3. Dysmenorrhea
14.4. Fever/Pyrexia
14.5. Migraine & Headache
14.6. Ophthalmic Pain & Inflammation
14.7. Osteoarthritis
14.8. Rheumatoid Arthritis
15. Non-steroidal Anti-inflammatory Drugs Market, by End User
15.1. Ambulatory Surgical Centers
15.2. Homecare
15.3. Hospitals
15.4. Specialty Clinics
16. Non-steroidal Anti-inflammatory Drugs Market, by Distribution Channel
16.1. Hospital Pharmacies
16.2. Online Pharmacies
16.3. Retail Pharmacies
17. Non-steroidal Anti-inflammatory Drugs Market, by Region
17.1. Americas
17.1.1. North America
17.1.2. Latin America
17.2. Europe, Middle East & Africa
17.2.1. Europe
17.2.2. Middle East
17.2.3. Africa
17.3. Asia-Pacific
18. Non-steroidal Anti-inflammatory Drugs Market, by Group
18.1. ASEAN
18.2. GCC
18.3. European Union
18.4. BRICS
18.5. G7
18.6. NATO
19. Non-steroidal Anti-inflammatory Drugs Market, by Country
19.1. United States
19.2. Canada
19.3. Mexico
19.4. Brazil
19.5. United Kingdom
19.6. Germany
19.7. France
19.8. Russia
19.9. Italy
19.10. Spain
19.11. China
19.12. India
19.13. Japan
19.14. Australia
19.15. South Korea
20. United States Non-steroidal Anti-inflammatory Drugs Market
21. China Non-steroidal Anti-inflammatory Drugs Market
22. Competitive Landscape
22.1. Market Concentration Analysis, 2025
22.1.1. Concentration Ratio (CR)
22.1.2. Herfindahl Hirschman Index (HHI)
22.2. Recent Developments & Impact Analysis, 2025
22.3. Product Portfolio Analysis, 2025
22.4. Benchmarking Analysis, 2025
22.5. Abbvie, Inc
22.6. Algen Healthcare Ltd.
22.7. Allegiant Health
22.8. Amgen Inc.
22.9. Amneal Pharmaceuticals LLC
22.10. Arcutis Biotherapeutics, Inc.
22.11. Astellas Pharma Inc.
22.12. AstraZeneca PLC
22.13. BASF SE
22.14. Bayer AG
22.15. Boehringer Ingelheim GmbH
22.16. Bristol-Myers Squibb Company
22.17. Clearsynth Labs Limited
22.18. Daiichi Sankyo Company, Limited
22.19. Dr. Reddy’s Laboratories Ltd.
22.20. Eisai Co., Ltd.
22.21. Eli Lilly and Company
22.22. EMS S.A.
22.23. Genentech, Inc. by F. Hoffmann-La Roche AG
22.24. Gilead Sciences, Inc.
22.25. GlaxoSmithKline PLC
22.26. Hikma Pharmaceuticals PLC
22.27. Incyte Corporation
22.28. Johnson & Johnson Services, Inc.
22.29. Merck KGaA
22.30. Novartis AG
22.31. Pfizer Inc.
22.32. Pharbest Pharmaceuticals, Inc.
22.33. Sandoz International GmbH
22.34. Sanofi S.A.
22.35. Spectrum Chemical Mfg. Corp.
22.36. Sun Pharmaceutical Industries Ltd.
22.37. Takeda Pharmaceutical Co. Ltd.
22.38. Teikoku Seiyaku Co., Ltd.
22.39. Teva Pharmaceutical Industries Ltd.
22.40. Verona Pharma plc
22.41. Viatris Inc.
List of Figures
FIGURE 1. GLOBAL NON-STEROIDAL ANTI-INFLAMMATORY DRUGS MARKET SIZE, 2018-2032 (USD MILLION)
FIGURE 2. GLOBAL NON-STEROIDAL ANTI-INFLAMMATORY DRUGS MARKET SHARE, BY KEY PLAYER, 2025
FIGURE 3. GLOBAL NON-STEROIDAL ANTI-INFLAMMATORY DRUGS MARKET, FPNV POSITIONING MATRIX, 2025
FIGURE 4. GLOBAL NON-STEROIDAL ANTI-INFLAMMATORY DRUGS MARKET SIZE, BY DRUG CLASS, 2025 VS 2026 VS 2032 (USD MILLION)
FIGURE 5. GLOBAL NON-STEROIDAL ANTI-INFLAMMATORY DRUGS MARKET SIZE, BY FORMULATION, 2025 VS 2026 VS 2032 (USD MILLION)
FIGURE 6. GLOBAL NON-STEROIDAL ANTI-INFLAMMATORY DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025 VS 2026 VS 2032 (USD MILLION)
FIGURE 7. GLOBAL NON-STEROIDAL ANTI-INFLAMMATORY DRUGS MARKET SIZE, BY PRESCRIPTION STATUS, 2025 VS 2026 VS 2032 (USD MILLION)
FIGURE 8. GLOBAL NON-STEROIDAL ANTI-INFLAMMATORY DRUGS MARKET SIZE, BY RELEASE TYPE, 2025 VS 2026 VS 2032 (USD MILLION)
FIGURE 9. GLOBAL NON-STEROIDAL ANTI-INFLAMMATORY DRUGS MARKET SIZE, BY PATIENT GROUP, 2025 VS 2026 VS 2032 (USD MILLION)
FIGURE 10. GLOBAL NON-STEROIDAL ANTI-INFLAMMATORY DRUGS MARKET SIZE, BY INDICATION, 2025 VS 2026 VS 2032 (USD MILLION)
FIGURE 11. GLOBAL NON-STEROIDAL ANTI-INFLAMMATORY DRUGS MARKET SIZE, BY END USER, 2025 VS 2026 VS 2032 (USD MILLION)
FIGURE 12. GLOBAL NON-STEROIDAL ANTI-INFLAMMATORY DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025 VS 2026 VS 2032 (USD MILLION)
FIGURE 13. GLOBAL NON-STEROIDAL ANTI-INFLAMMATORY DRUGS MARKET SIZE, BY REGION, 2025 VS 2026 VS 2032 (USD MILLION)
FIGURE 14. GLOBAL NON-STEROIDAL ANTI-INFLAMMATORY DRUGS MARKET SIZE, BY GROUP, 2025 VS 2026 VS 2032 (USD MILLION)
FIGURE 15. GLOBAL NON-STEROIDAL ANTI-INFLAMMATORY DRUGS MARKET SIZE, BY COUNTRY, 2025 VS 2026 VS 2032 (USD MILLION)
FIGURE 16. UNITED STATES NON-STEROIDAL ANTI-INFLAMMATORY DRUGS MARKET SIZE, 2018-2032 (USD MILLION)
FIGURE 17. CHINA NON-STEROIDAL ANTI-INFLAMMATORY DRUGS MARKET SIZE, 2018-2032 (USD MILLION)
List of Tables
TABLE 1. GLOBAL NON-STEROIDAL ANTI-INFLAMMATORY DRUGS MARKET SIZE, 2018-2032 (USD MILLION)
TABLE 2. GLOBAL NON-STEROIDAL ANTI-INFLAMMATORY DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
TABLE 3. GLOBAL NON-STEROIDAL ANTI-INFLAMMATORY DRUGS MARKET SIZE, BY ACETIC ACID DERIVATIVES, BY REGION, 2018-2032 (USD MILLION)
TABLE 4. GLOBAL NON-STEROIDAL ANTI-INFLAMMATORY DRUGS MARKET SIZE, BY ACETIC ACID DERIVATIVES, BY GROUP, 2018-2032 (USD MILLION)
TABLE 5. GLOBAL NON-STEROIDAL ANTI-INFLAMMATORY DRUGS MARKET SIZE, BY ACETIC ACID DERIVATIVES, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 6. GLOBAL NON-STEROIDAL ANTI-INFLAMMATORY DRUGS MARKET SIZE, BY ACETIC ACID DERIVATIVES, 2018-2032 (USD MILLION)
TABLE 7. GLOBAL NON-STEROIDAL ANTI-INFLAMMATORY DRUGS MARKET SIZE, BY DICLOFENAC, BY REGION, 2018-2032 (USD MILLION)
TABLE 8. GLOBAL NON-STEROIDAL ANTI-INFLAMMATORY DRUGS MARKET SIZE, BY DICLOFENAC, BY GROUP, 2018-2032 (USD MILLION)
TABLE 9. GLOBAL NON-STEROIDAL ANTI-INFLAMMATORY DRUGS MARKET SIZE, BY DICLOFENAC, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 10. GLOBAL NON-STEROIDAL ANTI-INFLAMMATORY DRUGS MARKET SIZE, BY KETOROLAC, BY REGION, 2018-2032 (USD MILLION)
TABLE 11. GLOBAL NON-STEROIDAL ANTI-INFLAMMATORY DRUGS MARKET SIZE, BY KETOROLAC, BY GROUP, 2018-2032 (USD MILLION)
TABLE 12. GLOBAL NON-STEROIDAL ANTI-INFLAMMATORY DRUGS MARKET SIZE, BY KETOROLAC, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 13. GLOBAL NON-STEROIDAL ANTI-INFLAMMATORY DRUGS MARKET SIZE, BY FENAMATES, BY REGION, 2018-2032 (USD MILLION)
TABLE 14. GLOBAL NON-STEROIDAL ANTI-INFLAMMATORY DRUGS MARKET SIZE, BY FENAMATES, BY GROUP, 2018-2032 (USD MILLION)
TABLE 15. GLOBAL NON-STEROIDAL ANTI-INFLAMMATORY DRUGS MARKET SIZE, BY FENAMATES, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 16. GLOBAL NON-STEROIDAL ANTI-INFLAMMATORY DRUGS MARKET SIZE, BY FENAMATES, 2018-2032 (USD MILLION)
TABLE 17. GLOBAL NON-STEROIDAL ANTI-INFLAMMATORY DRUGS MARKET SIZE, BY FLUFENAMIC ACID, BY REGION, 2018-2032 (USD MILLION)
TABLE 18. GLOBAL NON-STEROIDAL ANTI-INFLAMMATORY DRUGS MARKET SIZE, BY FLUFENAMIC ACID, BY GROUP, 2018-2032 (USD MILLION)
TABLE 19. GLOBAL NON-STEROIDAL ANTI-INFLAMMATORY DRUGS MARKET SIZE, BY FLUFENAMIC ACID, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 20. GLOBAL NON-STEROIDAL ANTI-INFLAMMATORY DRUGS MARKET SIZE, BY MEFENAMIC ACID, BY REGION, 2018-2032 (USD MILLION)
TABLE 21. GLOBAL NON-STEROIDAL ANTI-INFLAMMATORY DRUGS MARKET SIZE, BY MEFENAMIC ACID, BY GROUP, 2018-2032 (USD MILLION)
TABLE 22. GLOBAL NON-STEROIDAL ANTI-INFLAMMATORY DRUGS MARKET SIZE, BY MEFENAMIC ACID, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 23. GLOBAL NON-STEROIDAL ANTI-INFLAMMATORY DRUGS MARKET SIZE, BY OXICAMS, BY REGION, 2018-2032 (USD MILLION)
TABLE 24. GLOBAL NON-STEROIDAL ANTI-INFLAMMATORY DRUGS MARKET SIZE, BY OXICAMS, BY GROUP, 2018-2032 (USD MILLION)
TABLE 25. GLOBAL NON-STEROIDAL ANTI-INFLAMMATORY DRUGS MARKET SIZE, BY OXICAMS, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 26. GLOBAL NON-STEROIDAL ANTI-INFLAMMATORY DRUGS MARKET SIZE, BY OXICAMS, 2018-2032 (USD MILLION)
TABLE 27. GLOBAL NON-STEROIDAL ANTI-INFLAMMATORY DRUGS MARKET SIZE, BY PIROXICAM, BY REGION, 2018-2032 (USD MILLION)
TABLE 28. GLOBAL NON-STEROIDAL ANTI-INFLAMMATORY DRUGS MARKET SIZE, BY PIROXICAM, BY GROUP, 2018-2032 (USD MILLION)
TABLE 29. GLOBAL NON-STEROIDAL ANTI-INFLAMMATORY DRUGS MARKET SIZE, BY PIROXICAM, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 30. GLOBAL NON-STEROIDAL ANTI-INFLAMMATORY DRUGS MARKET SIZE, BY TENOXICAM, BY REGION, 2018-2032 (USD MILLION)
TABLE 31. GLOBAL NON-STEROIDAL ANTI-INFLAMMATORY DRUGS MARKET SIZE, BY TENOXICAM, BY GROUP, 2018-2032 (USD MILLION)
TABLE 32. GLOBAL NON-STEROIDAL ANTI-INFLAMMATORY DRUGS MARKET SIZE, BY TENOXICAM, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 33. GLOBAL NON-STEROIDAL ANTI-INFLAMMATORY DRUGS MARKET SIZE, BY PROPIONIC ACID DERIVATIVES, BY REGION, 2018-2032 (USD MILLION)
TABLE 34. GLOBAL NON-STEROIDAL ANTI-INFLAMMATORY DRUGS MARKET SIZE, BY PROPIONIC ACID DERIVATIVES, BY GROUP, 2018-2032 (USD MILLION)
TABLE 35. GLOBAL NON-STEROIDAL ANTI-INFLAMMATORY DRUGS MARKET SIZE, BY PROPIONIC ACID DERIVATIVES, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 36. GLOBAL NON-STEROIDAL ANTI-INFLAMMATORY DRUGS MARKET SIZE, BY PROPIONIC ACID DERIVATIVES, 2018-2032 (USD MILLION)
TABLE 37. GLOBAL NON-STEROIDAL ANTI-INFLAMMATORY DRUGS MARKET SIZE, BY FLURBIPROFEN, BY REGION, 2018-2032 (USD MILLION)
TABLE 38. GLOBAL NON-STEROIDAL ANTI-INFLAMMATORY DRUGS MARKET SIZE, BY FLURBIPROFEN, BY GROUP, 2018-2032 (USD MILLION)
TABLE 39. GLOBAL NON-STEROIDAL ANTI-INFLAMMATORY DRUGS MARKET SIZE, BY FLURBIPROFEN, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 40. GLOBAL NON-STEROIDAL ANTI-INFLAMMATORY DRUGS MARKET SIZE, BY IBUPROFEN, BY REGION, 2018-2032 (USD MILLION)
TABLE 41. GLOBAL NON-STEROIDAL ANTI-INFLAMMATORY DRUGS MARKET SIZE, BY IBUPROFEN, BY GROUP, 2018-2032 (USD MILLION)
TABLE 42. GLOBAL NON-STEROIDAL ANTI-INFLAMMATORY DRUGS MARKET SIZE, BY IBUPROFEN, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 43. GLOBAL NON-STEROIDAL ANTI-INFLAMMATORY DRUGS MARKET SIZE, BY KETOPROFEN, BY REGION, 2018-2032 (USD MILLION)
TABLE 44. GLOBAL NON-STEROIDAL ANTI-INFLAMMATORY DRUGS MARKET SIZE, BY KETOPROFEN, BY GROUP, 2018-2032 (USD MILLION)
TABLE 45. GLOBAL NON-STEROIDAL ANTI-INFLAMMATORY DRUGS MARKET SIZE, BY KETOPROFEN, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 46. GLOBAL NON-STEROIDAL ANTI-INFLAMMATORY DRUGS MARKET SIZE, BY NAPROXEN, BY REGION, 2018-2032 (USD MILLION)
TABLE 47. GLOBAL NON-STEROIDAL ANTI-INFLAMMATORY DRUGS MARKET SIZE, BY NAPROXEN, BY GROUP, 2018-2032 (USD MILLION)
TABLE 48. GLOBAL NON-STEROIDAL ANTI-INFLAMMATORY DRUGS MARKET SIZE, BY NAPROXEN, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 49. GLOBAL NON-STEROIDAL ANTI-INFLAMMATORY DRUGS MARKET SIZE, BY SALICYLATES, BY REGION, 2018-2032 (USD MILLION)
TABLE 50. GLOBAL NON-STEROIDAL ANTI-INFLAMMATORY DRUGS MARKET SIZE, BY SALICYLATES, BY GROUP, 2018-2032 (USD MILLION)
TABLE 51. GLOBAL NON-STEROIDAL ANTI-INFLAMMATORY DRUGS MARKET SIZE, BY SALICYLATES, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 52. GLOBAL NON-STEROIDAL ANTI-INFLAMMATORY DRUGS MARKET SIZE, BY SALICYLATES, 2018-2032 (USD MILLION)
TABLE 53. GLOBAL NON-STEROIDAL ANTI-INFLAMMATORY DRUGS MARKET SIZE, BY ASPIRIN, BY REGION, 2018-2032 (USD MILLION)
TABLE 54. GLOBAL NON-STEROIDAL ANTI-INFLAMMATORY DRUGS MARKET SIZE, BY ASPIRIN, BY GROUP, 2018-2032 (USD MILLION)
TABLE 55. GLOBAL NON-STEROIDAL ANTI-INFLAMMATORY DRUGS MARKET SIZE, BY ASPIRIN, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 56. GLOBAL NON-STEROIDAL ANTI-INFLAMMATORY DRUGS MARKET SIZE, BY DIFLUNISAL, BY REGION, 2018-2032 (USD MILLION)
TABLE 57. GLOBAL NON-STEROIDAL ANTI-INFLAMMATORY DRUGS MARKET SIZE, BY DIFLUNISAL, BY GROUP, 2018-2032 (USD MILLION)
TABLE 58. GLOBAL NON-STEROIDAL ANTI-INFLAMMATORY DRUGS MARKET SIZE, BY DIFLUNISAL, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 59. GLOBAL NON-STEROIDAL ANTI-INFLAMMATORY DRUGS MARKET SIZE, BY SELECTIVE COX-2 INHIBITORS (COXIBS), BY REGION, 2018-2032 (USD MILLION)
TABLE 60. GLOBAL NON-STEROIDAL ANTI-INFLAMMATORY DRUGS MARKET SIZE, BY SELECTIVE COX-2 INHIBITORS (COXIBS), BY GROUP, 2018-2032 (USD MILLION)
TABLE 61. GLOBAL NON-STEROIDAL ANTI-INFLAMMATORY DRUGS MARKET SIZE, BY SELECTIVE COX-2 INHIBITORS (COXIBS), BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 62. GLOBAL NON-STEROIDAL ANTI-INFLAMMATORY DRUGS MARKET SIZE, BY SELECTIVE COX-2 INHIBITORS (COXIBS), 2018-2032 (USD MILLION)
TABLE 63. GLOBAL NON-STEROIDAL ANTI-INFLAMMATORY DRUGS MARKET SIZE, BY CELECOXIB, BY REGION, 2018-2032 (USD MILLION)
TABLE 64. GLOBAL NON-STEROIDAL ANTI-INFLAMMATORY DRUGS MARKET SIZE, BY CELECOXIB, BY GROUP, 2018-2032 (USD MILLION)
TABLE 65. GLOBAL NON-STEROIDAL ANTI-INFLAMMATORY DRUGS MARKET SIZE, BY CELECOXIB, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 66. GLOBAL NON-STEROIDAL ANTI-INFLAMMATORY DRUGS MARKET SIZE, BY ETORICOXIB, BY REGION, 2018-2032 (USD MILLION)
TABLE 67. GLOBAL NON-STEROIDAL ANTI-INFLAMMATORY DRUGS MARKET SIZE, BY ETORICOXIB, BY GROUP, 2018-2032 (USD MILLION)
TABLE 68. GLOBAL NON-STEROIDAL ANTI-INFLAMMATORY DRUGS MARKET SIZE, BY ETORICOXIB, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 69. GLOBAL NON-STEROIDAL ANTI-INFLAMMATORY DRUGS MARKET SIZE, BY FORMULATION, 2018-2032 (USD MILLION)
TABLE 70. GLOBAL NON-STEROIDAL ANTI-INFLAMMATORY DRUGS MARKET SIZE, BY CAPSULES, BY REGION, 2018-2032 (USD MILLION)
TABLE 71. GLOBAL NON-STEROIDAL ANTI-INFLAMMATORY DRUGS MARKET SIZE, BY CAPSULES, BY GROUP, 2018-2032 (USD MILLION)
TABLE 72. GLOBAL NON-STEROIDAL ANTI-INFLAMMATORY DRUGS MARKET SIZE, BY CAPSULES, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 73. GLOBAL NON-STEROIDAL ANTI-INFLAMMATORY DRUGS MARKET SIZE, BY CREAMS/GELS, BY REGION, 2018-2032 (USD MILLION)
TABLE 74. GLOBAL NON-STEROIDAL ANTI-INFLAMMATORY DRUGS MARKET SIZE, BY CREAMS/GELS, BY GROUP, 2018-2032 (USD MILLION)
TABLE 75. GLOBAL NON-STEROIDAL ANTI-INFLAMMATORY DRUGS MARKET SIZE, BY CREAMS/GELS, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 76. GLOBAL NON-STEROIDAL ANTI-INFLAMMATORY DRUGS MARKET SIZE, BY POWDERS, BY REGION, 2018-2032 (USD MILLION)
TABLE 77. GLOBAL NON-STEROIDAL ANTI-INFLAMMATORY DRUGS MARKET SIZE, BY POWDERS, BY GROUP, 2018-2032 (USD MILLION)
TABLE 78. GLOBAL NON-STEROIDAL ANTI-INFLAMMATORY DRUGS MARKET SIZE, BY POWDERS, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 79. GLOBAL NON-STEROIDAL ANTI-INFLAMMATORY DRUGS MARKET SIZE, BY TABLETS, BY REGION, 2018-2032 (USD MILLION)
TABLE 80. GLOBAL NON-STEROIDAL ANTI-INFLAMMATORY DRUGS MARKET SIZE, BY TABLETS, BY GROUP, 2018-2032 (USD MILLION)
TABLE 81. GLOBAL NON-STEROIDAL ANTI-INFLAMMATORY DRUGS MARKET SIZE, BY TABLETS, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 82. GLOBAL NON-STEROIDAL ANTI-INFLAMMATORY DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
TABLE 83. GLOBAL NON-STEROIDAL ANTI-INFLAMMATORY DRUGS MARKET SIZE, BY ORAL, BY REGION, 2018-2032 (USD MILLION)
TABLE 84. GLOBAL NON-STEROIDAL ANTI-INFLAMMATORY DRUGS MARKET SIZE, BY ORAL, BY GROUP, 2018-2032 (USD MILLION)
TABLE 85. GLOBAL NON-STEROIDAL ANTI-INFLAMMATORY DRUGS MARKET SIZE, BY ORAL, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 86. GLOBAL NON-STEROIDAL ANTI-INFLAMMATORY DRUGS MARKET SIZE, BY PARENTERAL, BY REGION, 2018-2032 (USD MILLION)
TABLE 87. GLOBAL NON-STEROIDAL ANTI-INFLAMMATORY DRUGS MARKET SIZE, BY PARENTERAL, BY GROUP, 2018-2032 (USD MILLION)
TABLE 88. GLOBAL NON-STEROIDAL ANTI-INFLAMMATORY DRUGS MARKET SIZE, BY PARENTERAL, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 89. GLOBAL NON-STEROIDAL ANTI-INFLAMMATORY DRUGS MARKET SIZE, BY TOPICAL, BY REGION, 2018-2032 (USD MILLION)
TABLE 90. GLOBAL NON-STEROIDAL ANTI-INFLAMMATORY DRUGS MARKET SIZE, BY TOPICAL, BY GROUP, 2018-2032 (USD MILLION)
TABLE 91. GLOBAL NON-STEROIDAL ANTI-INFLAMMATORY DRUGS MARKET SIZE, BY TOPICAL, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 92. GLOBAL NON-STEROIDAL ANTI-INFLAMMATORY DRUGS MARKET SIZE, BY PRESCRIPTION STATUS, 2018-2032 (USD MILLION)
TABLE 93. GLOBAL NON-STEROIDAL ANTI-INFLAMMATORY DRUGS MARKET SIZE, BY OVER-THE-COUNTER, BY REGION, 2018-2032 (USD MILLION)
TABLE 94. GLOBAL NON-STEROIDAL ANTI-INFLAMMATORY DRUGS MARKET SIZE, BY OVER-THE-COUNTER, BY GROUP, 2018-2032 (USD MILLION)
TABLE 95. GLOBAL NON-STEROIDAL ANTI-INFLAMMATORY DRUGS MARKET SIZE, BY OVER-THE-COUNTER, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 96. GLOBAL NON-STEROIDAL ANTI-INFLAMMATORY DRUGS MARKET SIZE, BY PRESCRIPTION ONLY, BY REGION, 2018-2032 (USD MILLION)
TABLE 97. GLOBAL NON-STEROIDAL ANTI-INFLAMMATORY DRUGS MARKET SIZE, BY PRESCRIPTION ONLY, BY GROUP, 2018-2032 (USD MILLION)
TABLE 98. GLOBAL NON-STEROIDAL ANTI-INFLAMMATORY DRUGS MARKET SIZE, BY PRESCRIPTION ONLY, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 99. GLOBAL NON-STEROIDAL ANTI-INFLAMMATORY DRUGS MARKET SIZE, BY RELEASE TYPE, 2018-2032 (USD MILLION)
TABLE 100. GLOBAL NON-STEROIDAL ANTI-INFLAMMATORY DRUGS MARKET SIZE, BY IMMEDIATE-RELEASE, BY REGION, 2018-2032 (USD MILLION)
TABLE 101. GLOBAL NON-STEROIDAL ANTI-INFLAMMATORY DRUGS MARKET SIZE, BY IMMEDIATE-RELEASE, BY GROUP, 2018-2032 (USD MILLION)
TABLE 102. GLOBAL NON-STEROIDAL ANTI-INFLAMMATORY DRUGS MARKET SIZE, BY IMMEDIATE-RELEASE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 103. GLOBAL NON-STEROIDAL ANTI-INFLAMMATORY DRUGS MARKET SIZE, BY MODIFIED-RELEASE, BY REGION, 2018-2032 (USD MILLION)
TABLE 104. GLOBAL NON-STEROIDAL ANTI-INFLAMMATORY DRUGS MARKET SIZE, BY MODIFIED-RELEASE, BY GROUP, 2018-2032 (USD MILLION)
TABLE 105. GLOBAL NON-STEROIDAL ANTI-INFLAMMATORY DRUGS MARKET SIZE, BY MODIFIED-RELEASE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 106. GLOBAL NON-STEROIDAL ANTI-INFLAMMATORY DRUGS MARKET SIZE, BY MODIFIED-RELEASE, 2018-2032 (USD MILLION)
TABLE 107. GLOBAL NON-STEROIDAL ANTI-INFLAMMATORY DRUGS MARKET SIZE, BY CONTROLLED-RELEASE, BY REGION, 2018-2032 (USD MILLION)
TABLE 108. GLOBAL NON-STEROIDAL ANTI-INFLAMMATORY DRUGS MARKET SIZE, BY CONTROLLED-RELEASE, BY GROUP, 2018-2032 (USD MILLION)
TABLE 109. GLOBAL NON-STEROIDAL ANTI-INFLAMMATORY DRUGS MARKET SIZE, BY CONTROLLED-RELEASE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 110. GLOBAL NON-STEROIDAL ANTI-INFLAMMATORY DRUGS MARKET SIZE, BY DELAYED-RELEASE/ENTERIC-COATED, BY REGION, 2018-2032 (USD MILLION)
TABLE 111. GLOBAL NON-STEROIDAL ANTI-INFLAMMATORY DRUGS MARKET SIZE, BY DELAYED-RELEASE/ENTERIC-COATED, BY GROUP, 2018-2032 (USD MILLION)
TABLE 112. GLOBAL NON-STEROIDAL ANTI-INFLAMMATORY DRUGS MARKET SIZE, BY DELAYED-RELEASE/ENTERIC-COATED, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 113. GLOBAL NON-STEROIDAL ANTI-INFLAMMATORY DRUGS MARKET SIZE, BY EXTENDED-RELEASE, BY REGION, 2018-2032 (USD MILLION)
TABLE 114. GLOBAL NON-STEROIDAL ANTI-INFLAMMATORY DRUGS MARKET SIZE, BY EXTENDED-RELEASE, BY GROUP, 2018-2032 (USD MILLION)
TABLE 115. GLOBAL NON-STEROIDAL ANTI-INFLAMMATORY DRUGS MARKET SIZE, BY EXTENDED-RELEASE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 116. GLOBAL NON-STEROIDAL ANTI-INFLAMMATORY DRUGS MARKET SIZE, BY PATIENT GROUP, 2018-2032 (USD MILLION)
TABLE 117. GLOBAL NON-STEROIDAL ANTI-INFLAMMATORY DRUGS MARKET SIZE, BY ADULTS, BY REGION, 2018-2032 (USD MILLION)
TABLE 118. GLOBAL NON-STEROIDAL ANTI-INFLAMMATORY DRUGS MARKET SIZE, BY ADULTS, BY GROUP, 2018-2032 (USD MILLION)
TABLE 119. GLOBAL NON-STEROIDAL ANTI-INFLAMMATORY DRUGS MARKET SIZE, BY ADULTS, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 120. GLOBAL NON-STEROIDAL ANTI-INFLAMMATORY DRUGS MARKET SIZE, BY GERIATRIC, BY REGION, 2018-2032 (USD MILLION)
TABLE 121. GLOBAL NON-STEROIDAL ANTI-INFLAMMATORY DRUGS MARKET SIZE, BY GERIATRIC, BY GROUP, 2018-2032 (USD MILLION)
TABLE 122. GLOBAL NON-STEROIDAL ANTI-INFLAMMATORY DRUGS MARKET SIZE, BY GERIATRIC, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 123. GLOBAL NON-STEROIDAL ANTI-INFLAMMATORY DRUGS MARKET SIZE, BY PEDIATRIC, BY REGION, 2018-2032 (USD MILLION)
TABLE 124. GLOBAL NON-STEROIDAL ANTI-INFLAMMATORY DRUGS MARKET SIZE, BY PEDIATRIC, BY GROUP, 2018-2032 (USD MILLION)
TABLE 125. GLOBAL NON-STEROIDAL ANTI-INFLAMMATORY DRUGS MARKET SIZE, BY PEDIATRIC, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 126. GLOBAL NON-STEROIDAL ANTI-INFLAMMATORY DRUGS MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
TABLE 127. GLOBAL NON-STEROIDAL ANTI-INFLAMMATORY DRUGS MARKET SIZE, BY ACUTE PAIN, BY REGION, 2018-2032 (USD MILLION)
TABLE 128. GLOBAL NON-STEROIDAL ANTI-INFLAMMATORY DRUGS MARKET SIZE, BY ACUTE PAIN, BY GROUP, 2018-2032 (USD MILLION)
TABLE 129. GLOBAL NON-STEROIDAL ANTI-INFLAMMATORY DRUGS MARKET SIZE, BY ACUTE PAIN, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 130. GLOBAL NON-STEROIDAL ANTI-INFLAMMATORY DRUGS MARKET SIZE, BY ACUTE PAIN, 2018-2032 (USD MILLION)
TABLE 131. GLOBAL NON-STEROIDAL ANTI-INFLAMMATORY DRUGS MARKET SIZE, BY DENTAL PAIN, BY REGION, 2018-2032 (USD MILLION)
TABLE 132. GLOBAL NON-STEROIDAL ANTI-INFLAMMATORY DRUGS MARKET SIZE, BY DENTAL PAIN, BY GROUP, 2018-2032 (USD MILLION)
TABLE 133. GLOBAL NON-STEROIDAL ANTI-INFLAMMATORY DRUGS MARKET SIZE, BY DENTAL PAIN, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 134. GLOBAL NON-STEROIDAL ANTI-INFLAMMATORY DRUGS MARKET SIZE, BY MUSCULOSKELETAL INJURY (SPRAIN/STRAIN), BY REGION, 2018-2032 (USD MILLION)
TABLE 135. GLOBAL NON-STEROIDAL ANTI-INFLAMMATORY DRUGS MARKET SIZE, BY MUSCULOSKELETAL INJURY (SPRAIN/STRAIN), BY GROUP, 2018-2032 (USD MILLION)
TABLE 136. GLOBAL NON-STEROIDAL ANTI-INFLAMMATORY DRUGS MARKET SIZE, BY MUSCULOSKELETAL INJURY (SPRAIN/STRAIN), BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 137. GLOBAL NON-STEROIDAL ANTI-INFLAMMATORY DRUGS MARKET SIZE, BY POSTOPERATIVE PAIN, BY REGION, 2018-2032 (USD MILLION)
TABLE 138. GLOBAL NON-STEROIDAL ANTI-INFLAMMATORY DRUGS MARKET SIZE, BY POSTOPERATIVE PAIN, BY GROUP, 2018-2032 (USD MILLION)
TABLE 139. GLOBAL NON-STEROIDAL ANTI-INFLAMMATORY DRUGS MARKET SIZE, BY POSTOPERATIVE PAIN, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 140. GLOBAL NON-STEROIDAL ANTI-INFLAMMATORY DRUGS MARKET SIZE, BY ANKYLOSING SPONDYLITIS, BY REGION, 2018-2032 (USD MILLION)
TABLE 141. GLOBAL NON-STEROIDAL ANTI-INFLAMMATORY DRUGS MARKET SIZE, BY ANKYLOSING SPONDYLITIS, BY GROUP, 2018-2032 (USD MILLION)
TABLE 142. GLOBAL NON-STEROIDAL ANTI-INFLAMMATORY DRUGS MARKET SIZE, BY ANKYLOSING SPONDYLITIS, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 143. GLOBAL NON-STEROIDAL ANTI-INFLAMMATORY DRUGS MARKET SIZE, BY DYSMENORRHEA, BY REGION, 2018-2032 (USD MILLION)
TABLE 144. GLOBAL NON-STEROIDAL ANTI-INFLAMMATORY DRUGS MARKET SIZE, BY DYSMENORRHEA, BY GROUP, 2018-2032 (USD MILLION)
TABLE 145. GLOBAL NON-STEROIDAL ANTI-INFLAMMATORY DRUGS MARKET SIZE, BY DYSMENORRHEA, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 146. GLOBAL NON-STEROIDAL ANTI-INFLAMMATORY DRUGS MARKET SIZE, BY FEVER/PYREXIA, BY REGION, 2018-2032 (USD MILLION)
TABLE 147. GLOBAL NON-STEROIDAL ANTI-INFLAMMATORY DRUGS MARKET SIZE, BY FEVER/PYREXIA, BY GROUP, 2018-2032 (USD MILLION)
TABLE 148. GLOBAL NON-STEROIDAL ANTI-INFLAMMATORY DRUGS MARKET SIZE, BY FEVER/PYREXIA, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 149. GLOBAL NON-STEROIDAL ANTI-INFLAMMATORY DRUGS MARKET SIZE, BY MIGRAINE & HEADACHE, BY REGION, 2018-2032 (USD MILLION)
TABLE 150. GLOBAL NON-STEROIDAL ANTI-INFLAMMATORY DRUGS MARKET SIZE, BY MIGRAINE & HEADACHE, BY GROUP, 2018-2032 (USD MILLION)
TABLE 151. GLOBAL NON-STEROIDAL ANTI-INFLAMMATORY DRUGS MARKET SIZE, BY MIGRAINE & HEADACHE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 152. GLOBAL NON-STEROIDAL ANTI-INFLAMMATORY DRUGS MARKET SIZE, BY OPHTHALMIC PAIN & INFLAMMATION, BY REGION, 2018-2032 (USD MILLION)
TABLE 153. GLOBAL NON-STEROIDAL ANTI-INFLAMMATORY DRUGS MARKET SIZE, BY OPHTHALMIC PAIN & INFLAMMATION, BY GROUP, 2018-2032 (USD MILLION)
TABLE 154. GLOBAL NON-STEROIDAL ANTI-INFLAMMATORY DRUGS MARKET SIZE, BY OPHTHALMIC PAIN & INFLAMMATION, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 155. GLOBAL NON-STEROIDAL ANTI-INFLAMMATORY DRUGS MARKET SIZE, BY OSTEOARTHRITIS, BY REGION, 2018-2032 (USD MILLION)
TABLE 156. GLOBAL NON-STEROIDAL ANTI-INFLAMMATORY DRUGS MARKET SIZE, BY OSTEOARTHRITIS, BY GROUP, 2018-2032 (USD MILLION)
TABLE 157. GLOBAL NON-STEROIDAL ANTI-INFLAMMATORY DRUGS MARKET SIZE, BY OSTEOARTHRITIS, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 158. GLOBAL NON-STEROIDAL ANTI-INFLAMMATORY DRUGS MARKET SIZE, BY RHEUMATOID ARTHRITIS, BY REGION, 2018-2032 (USD MILLION)
TABLE 159. GLOBAL NON-STEROIDAL ANTI-INFLAMMATORY DRUGS MARKET SIZE, BY RHEUMATOID ARTHRITIS, BY GROUP, 2018-2032 (USD MILLION)
TABLE 160. GLOBAL NON-STEROIDAL ANTI-INFLAMMATORY DRUGS MARKET SIZE, BY RHEUMATOID ARTHRITIS, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 161. GLOBAL NON-STEROIDAL ANTI-INFLAMMATORY DRUGS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
TABLE 162. GLOBAL NON-STEROIDAL ANTI-INFLAMMATORY DRUGS MARKET SIZE, BY AMBULATORY SURGICAL CENTERS, BY REGION, 2018-2032 (USD MILLION)
TABLE 163. GLOBAL NON-STEROIDAL ANTI-INFLAMMATORY DRUGS MARKET SIZE, BY AMBULATORY SURGICAL CENTERS, BY GROUP, 2018-2032 (USD MILLION)
TABLE 164. GLOBAL NON-STEROIDAL ANTI-INFLAMMATORY DRUGS MARKET SIZE, BY AMBULATORY SURGICAL CENTERS, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 165. GLOBAL NON-STEROIDAL ANTI-INFLAMMATORY DRUGS MARKET SIZE, BY HOMECARE, BY REGION, 2018-2032 (USD MILLION)
TABLE 166. GLOBAL NON-STEROIDAL ANTI-INFLAMMATORY DRUGS MARKET SIZE, BY HOMECARE, BY GROUP, 2018-2032 (USD MILLION)
TABLE 167. GLOBAL NON-STEROIDAL ANTI-INFLAMMATORY DRUGS MARKET SIZE, BY HOMECARE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 168. GLOBAL NON-STEROIDAL ANTI-INFLAMMATORY DRUGS MARKET SIZE, BY HOSPITALS, BY REGION, 2018-2032 (USD MILLION)
TABLE 169. GLOBAL NON-STEROIDAL ANTI-INFLAMMATORY DRUGS MARKET SIZE, BY HOSPITALS, BY GROUP, 2018-2032 (USD MILLION)
TABLE 170. GLOBAL NON-STEROIDAL ANTI-INFLAMMATORY DRUGS MARKET SIZE, BY HOSPITALS, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 171. GLOBAL NON-STEROIDAL ANTI-INFLAMMATORY DRUGS MARKET SIZE, BY SPECIALTY CLINICS, BY REGION, 2018-2032 (USD MILLION)
TABLE 172. GLOBAL NON-STEROIDAL ANTI-INFLAMMATORY DRUGS MARKET SIZE, BY SPECIALTY CLINICS, BY GROUP, 2018-2032 (USD MILLION)
TABLE 173. GLOBAL NON-STEROIDAL ANTI-INFLAMMATORY DRUGS MARKET SIZE, BY SPECIALTY CLINICS, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 174. GLOBAL NON-STEROIDAL ANTI-INFLAMMATORY DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
TABLE 175. GLOBAL NON-STEROIDAL ANTI-INFLAMMATORY DRUGS MARKET SIZE, BY HOSPITAL PHARMACIES, BY REGION, 2018-2032 (USD MILLION)
TABLE 176. GLOBAL NON-STEROIDAL ANTI-INFLAMMATORY DRUGS MARKET SIZE, BY HOSPITAL PHARMACIES, BY GROUP, 2018-2032 (USD MILLION)
TABLE 177. GLOBAL NON-STEROIDAL ANTI-INFLAMMATORY DRUGS MARKET SIZE, BY HOSPITAL PHARMACIES, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 178. GLOBAL NON-STEROIDAL ANTI-INFLAMMATORY DRUGS MARKET SIZE, BY ONLINE PHARMACIES, BY REGION, 2018-2032 (USD MILLION)
TABLE 179. GLOBAL NON-STEROIDAL ANTI-INFLAMMATORY DRUGS MARKET SIZE, BY ONLINE PHARMACIES, BY GROUP, 2018-2032 (USD MILLION)
TABLE 180. GLOBAL NON-STEROIDAL ANTI-INFLAMMATORY DRUGS MARKET SIZE, BY ONLINE PHARMACIES, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 181. GLOBAL NON-STEROIDAL ANTI-INFLAMMATORY DRUGS MARKET SIZE, BY RETAIL PHARMACIES, BY REGION, 2018-2032 (USD MILLION)
TABLE 182. GLOBAL NON-STEROIDAL ANTI-INFLAMMATORY DRUGS MARKET SIZE, BY RETAIL PHARMACIES, BY GROUP, 2018-2032 (USD MILLION)
TABLE 183. GLOBAL NON-STEROIDAL ANTI-INFLAMMATORY DRUGS MARKET SIZE, BY RETAIL PHARMACIES, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 184. GLOBAL NON-STEROIDAL ANTI-INFLAMMATORY DRUGS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
TABLE 185. AMERICAS NON-STEROIDAL ANTI-INFLAMMATORY DRUGS MARKET SIZE, BY SUBREGION, 2018-2032 (USD MILLION)
TABLE 186. AMERICAS NON-STEROIDAL ANTI-INFLAMMATORY DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
TABLE 187. AMERICAS NON-STEROIDAL ANTI-INFLAMMATORY DRUGS MARKET SIZE, BY ACETIC ACID DERIVATIVES, 2018-2032 (USD MILLION)
TABLE 188. AMERICAS NON-STEROIDAL ANTI-INFLAMMATORY DRUGS MARKET SIZE, BY FENAMATES, 2018-2032 (USD MILLION)
TABLE 189. AMERICAS NON-STEROIDAL ANTI-INFLAMMATORY DRUGS MARKET SIZE, BY OXICAMS, 2018-2032 (USD MILLION)
TABLE 190. AMERICAS NON-STEROIDAL ANTI-INFLAMMATORY DRUGS MARKET SIZE, BY PROPIONIC ACID DERIVATIVES, 2018-2032 (USD MILLION)
TABLE 191. AMERICAS NON-STEROIDAL ANTI-INFLAMMATORY DRUGS MARKET SIZE, BY SALICYLATES, 2018-2032 (USD MILLION)
TABLE 192. AMERICAS NON-STEROIDAL ANTI-INFLAMMATORY DRUGS MARKET SIZE, BY SELECTIVE COX-2 INHIBITORS (COXIBS), 2018-2032 (USD MILLION)
TABLE 193. AMERICAS NON-STEROIDAL ANTI-INFLAMMATORY DRUGS MARKET SIZE, BY FORMULATION, 2018-2032 (USD MILLION)
TABLE 194. AMERICAS NON-STEROIDAL ANTI-INFLAMMATORY DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
TABLE 195. AMERICAS NON-STEROIDAL ANTI-INFLAMMATORY DRUGS MARKET SIZE, BY PRESCRIPTION STATUS, 2018-2032 (USD MILLION)
TABLE 196. AMERICAS NON-STEROIDAL ANTI-INFLAMMATORY DRUGS MARKET SIZE, BY RELEASE TYPE, 2018-2032 (USD MILLION)
TABLE 197. AMERICAS NON-STEROIDAL ANTI-INFLAMMATORY DRUGS MARKET SIZE, BY MODIFIED-RELEASE, 2018-2032 (USD MILLION)
TABLE 198. AMERICAS NON-STEROIDAL ANTI-INFLAMMATORY DRUGS MARKET SIZE, BY PATIENT GROUP, 2018-2032 (USD MILLION)
TABLE 199. AMERICAS NON-STEROIDAL ANTI-INFLAMMATORY DRUGS MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
TABLE 200. AMERICAS NON-STEROIDAL ANTI-INFLAMMATORY DRUGS MARKET SIZE, BY ACUTE PAIN, 2018-2032 (USD MILLION)
TABLE 201. AMERICAS NON-STEROIDAL ANTI-INFLAMMATORY DRUGS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
TABLE 202. AMERICAS NON-STEROIDAL ANTI-INFLAMMATORY DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
TABLE 203. NORTH AMERICA NON-STEROIDAL ANTI-INFLAMMATORY DRUGS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 204. NORTH AMERICA NON-STEROIDAL ANTI-INFLAMMATORY DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
TABLE 205. NORTH AMERICA NON-STEROIDAL ANTI-INFLAMMATORY DRUGS MARKET SIZE, BY ACETIC ACID DERIVATIVES, 2018-2032 (USD MILLION)
TABLE 206. NORTH AMERICA NON-STEROIDAL ANTI-INFLAMMATORY DRUGS MARKET SIZE, BY FENAMATES, 2018-2032 (USD MILLION)
TABLE 207. NORTH AMERICA NON-STEROIDAL ANTI-INFLAMMATORY DRUGS MARKET SIZE, BY OXICAMS, 2018-2032 (USD MILLION)
TABLE 208. NORTH AMERICA NON-STEROIDAL ANTI-INFLAMMATORY DRUGS MARKET SIZE, BY PROPIONIC ACID DERIVATIVES, 2018-2032 (USD MILLION)
TABLE 209. NORTH AMERICA NON-STEROIDAL ANTI-INFLAMMATORY DRUGS MARKET SIZE, BY SALICYLATES, 2018-2032 (USD MILLION)
TABLE 210. NORTH AMERICA NON-STEROIDAL ANTI-INFLAMMATORY DRUGS MARKET SIZE, BY SELECTIVE COX-2 INHIBITORS (COXIBS), 2018-2032 (USD MILLION)
TABLE 211. NORTH AMERICA NON-STEROIDAL ANTI-INFLAMMATORY DRUGS MARKET SIZE, BY FORMULATION, 2018-2032 (USD MILLION)
TABLE 212. NORTH AMERICA NON-STEROIDAL ANTI-INFLAMMATORY DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
TABLE 213. NORTH AMERICA NON-STEROIDAL ANTI-INFLAMMATORY DRUGS MARKET SIZE, BY PRESCRIPTION STATUS, 2018-2032 (USD MILLION)
TABLE 214. NORTH AMERICA NON-STEROIDAL ANTI-INFLAMMATORY DRUGS MARKET SIZE, BY RELEASE TYPE, 2018-2032 (USD MILLION)
TABLE 215. NORTH AMERICA NON-STEROIDAL ANTI-INFLAMMATORY DRUGS MARKET SIZE, BY MODIFIED-RELEASE, 2018-2032 (USD MILLION)
TABLE 216. NORTH AMERICA NON-STEROIDAL ANTI-INFLAMMATORY DRUGS MARKET SIZE, BY PATIENT GROUP, 2018-2032 (USD MILLION)
TABLE 217. NORTH AMERICA NON-STEROIDAL ANTI-INFLAMMATORY DRUGS MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
TABLE 218. NORTH AMERICA NON-STEROIDAL ANTI-INFLAMMATORY DRUGS MARKET SIZE, BY ACUTE PAIN, 2018-2032 (USD MILLION)
TABLE 219. NORTH AMERICA NON-STEROIDAL ANTI-INFLAMMATORY DRUGS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
TABLE 220. NORTH AMERICA NON-STEROIDAL ANTI-INFLAMMATORY DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
TABLE 221. LATIN AMERICA NON-STEROIDAL ANTI-INFLAMMATORY DRUGS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 222. LATIN AMERICA NON-STEROIDAL ANTI-INFLAMMATORY DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
TABLE 223. LATIN AMERICA NON-STEROIDAL ANTI-INFLAMMATORY DRUGS MARKET SIZE, BY ACETIC ACID DERIVATIVES, 2018-2032 (USD MILLION)
TABLE 224. LATIN AMERICA NON-STEROIDAL ANTI-INFLAMMATORY DRUGS MARKET SIZE, BY FENAMATES, 2018-2032 (USD MILLION)
TABLE 225. LATIN AMERICA NON-STEROIDAL ANTI-INFLAMMATORY DRUGS MARKET SIZE, BY OXICAMS, 2018-2032 (USD MILLION)
TABLE 226. LATIN AMERICA NON-STEROIDAL ANTI-INFLAMMATORY DRUGS MARKET SIZE, BY PROPIONIC ACID DERIVATIVES, 2018-2032 (USD MILLION)
TABLE 227. LATIN AMERICA NON-STEROIDAL ANTI-INFLAMMATORY DRUGS MARKET SIZE, BY SALICYLATES, 2018-2032 (USD MILLION)
TABLE 228. LATIN AMERICA NON-STEROIDAL ANTI-INFLAMMATORY DRUGS MARKET SIZE, BY SELECTIVE COX-2 INHIBITORS (COXIBS), 2018-2032 (USD MILLION)
TABLE 229. LATIN AMERICA NON-STEROIDAL ANTI-INFLAMMATORY DRUGS MARKET SIZE, BY FORMULATION, 2018-2032 (USD MILLION)
TABLE 230. LATIN AMERICA NON-STEROIDAL ANTI-INFLAMMATORY DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
TABLE 231. LATIN AMERICA NON-STEROIDAL ANTI-INFLAMMATORY DRUGS MARKET SIZE, BY PRESCRIPTION STATUS, 2018-2032 (USD MILLION)
TABLE 232. LATIN AMERICA NON-STEROIDAL ANTI-INFLAMMATORY DRUGS MARKET SIZE, BY RELEASE TYPE, 2018-2032 (USD MILLION)
TABLE 233. LATIN AMERICA NON-STEROIDAL ANTI-INFLAMMATORY DRUGS MARKET SIZE, BY MODIFIED-RELEASE, 2018-2032 (USD MILLION)
TABLE 234. LATIN AMERICA NON-STEROIDAL ANTI-INFLAMMATORY DRUGS MARKET SIZE, BY PATIENT GROUP, 2018-2032 (USD MILLION)
TABLE 235. LATIN AMERICA NON-STEROIDAL ANTI-INFLAMMATORY DRUGS MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
TABLE 236. LATIN AMERICA NON-STEROIDAL ANTI-INFLAMMATORY DRUGS MARKET SIZE, BY ACUTE PAIN, 2018-2032 (USD MILLION)
TABLE 237. LATIN AMERICA NON-STEROIDAL ANTI-INFLAMMATORY DRUGS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
TABLE 238. LATIN AMERICA NON-STEROIDAL ANTI-INFLAMMATORY DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
TABLE 239. EUROPE, MIDDLE EAST & AFRICA NON-STEROIDAL ANTI-INFLAMMATORY DRUGS MARKET SIZE, BY SUBREGION, 2018-2032 (USD MILLION)
TABLE 240. EUROPE, MIDDLE EAST & AFRICA NON-STEROIDAL ANTI-INFLAMMATORY DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
TABLE 241. EUROPE, MIDDLE EAST & AFRICA NON-STEROIDAL ANTI-INFLAMMATORY DRUGS MARKET SIZE, BY ACETIC ACID DERIVATIVES, 2018-2032 (USD MILLION)
TABLE 242. EUROPE, MIDDLE EAST & AFRICA NON-STEROIDAL ANTI-INFLAMMATORY DRUGS MARKET SIZE, BY FENAMATES, 2018-2032 (USD MILLION)
TABLE 243. EUROPE, MIDDLE EAST & AFRICA NON-STEROIDAL ANTI-INFLAMMATORY DRUGS MARKET SIZE, BY OXICAMS, 2018-2032 (USD MILLION)
TABLE 244. EUROPE, MIDDLE EAST & AFRICA NON-STEROIDAL ANTI-INFLAMMATORY DRUGS MARKET SIZE, BY PROPIONIC ACID DERIVATIVES, 2018-2032 (USD MILLION)
TABLE 245. EUROPE, MIDDLE EAST & AFRICA NON-STEROIDAL ANTI-INFLAMMATORY DRUGS MARKET SIZE, BY SALICYLATES, 2018-2032 (USD MILLION)
TABLE 246. EUROPE, MIDDLE EAST & AFRICA NON-STEROIDAL ANTI-INFLAMMATORY DRUGS MARKET SIZE, BY SELECTIVE COX-2 INHIBITORS (COXIBS), 2018-2032 (USD MILLION)
TABLE 247. EUROPE, MIDDLE EAST & AFRICA NON-STEROIDAL ANTI-INFLAMMATORY DRUGS MARKET SIZE, BY FORMULATION, 2018-2032 (USD MILLION)
TABLE 248. EUROPE, MIDDLE EAST & AFRICA NON-STEROIDAL ANTI-INFLAMMATORY DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
TABLE 249. EUROPE, MIDDLE EAST & AFRICA NON-STEROIDAL ANTI-INFLAMMATORY DRUGS MARKET SIZE, BY PRESCRIPTION STATUS, 2018-2032 (USD MILLION)
TABLE 250. EUROPE, MIDDLE EAST & AFRICA NON-STEROIDAL ANTI-INFLAMMATORY DRUGS MARKET SIZE, BY RELEASE TYPE, 2018-2032 (USD MILLION)
TABLE 251. EUROPE, MIDDLE EAST & AFRICA NON-STEROIDAL ANTI-INFLAMMATORY DRUGS MARKET SIZE, BY MODIFIED-RELEASE, 2018-2032 (USD MILLION)
TABLE 252. EUROPE, MIDDLE EAST & AFRICA NON-STEROIDAL ANTI-INFLAMMATORY DRUGS MARKET SIZE, BY PATIENT GROUP, 2018-2032 (USD MILLION)
TABLE 253. EUROPE, MIDDLE EAST & AFRICA NON-STEROIDAL ANTI-INFLAMMATORY DRUGS MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
TABLE 254. EUROPE, MIDDLE EAST & AFRICA NON-STEROIDAL ANTI-INFLAMMATORY DRUGS MARKET SIZE, BY ACUTE PAIN, 2018-2032 (USD MILLION)
TABLE 255. EUROPE, MIDDLE EAST & AFRICA NON-STEROIDAL ANTI-INFLAMMATORY DRUGS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
TABLE 256. EUROPE, MIDDLE EAST & AFRICA NON-STEROIDAL ANTI-INFLAMMATORY DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
TABLE 257. EUROPE NON-STEROIDAL ANTI-INFLAMMATORY DRUGS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 258. EUROPE NON-STEROIDAL ANTI-INFLAMMATORY DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
TABLE 259. EUROPE NON-STEROIDAL ANTI-INFLAMMATORY DRUGS MARKET SIZE, BY ACETIC ACID DERIVATIVES, 2018-2032 (USD MILLION)
TABLE 260. EUROPE NON-STEROIDAL ANTI-INFLAMMATORY DRUGS MARKET SIZE, BY FENAMATES, 2018-2032 (USD MILLION)
TABLE 261. EUROPE NON-STEROIDAL ANTI-INFLAMMATORY DRUGS MARKET SIZE, BY OXICAMS, 2018-2032 (USD MILLION)
TABLE 262. EUROPE NON-STEROIDAL ANTI-INFLAMMATORY DRUGS MARKET SIZE, BY PROPIONIC ACID DERIVATIVES, 2018-2032 (USD MILLION)
TABLE 263. EUROPE NON-STEROIDAL ANTI-INFLAMMATORY DRUGS MARKET SIZE, BY SALICYLATES, 2018-2032 (USD MILLION)
TABLE 264. EUROPE NON-STEROIDAL ANTI-INFLAMMATORY DRUGS MARKET SIZE, BY SELECTIVE COX-2 INHIBITORS (COXIBS), 2018-2032 (USD MILLION)
TABLE 265. EUROPE NON-STEROIDAL ANTI-INFLAMMATORY DRUGS MARKET SIZE, BY FORMULATION, 2018-2032 (USD MILLION)
TABLE 266. EUROPE NON-STEROIDAL ANTI-INFLAMMATORY DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
TABLE 267. EUROPE NON-STEROIDAL ANTI-INFLAMMATORY DRUGS MARKET SIZE, BY PRESCRIPTION STATUS, 2018-2032 (USD MILLION)
TABLE 268. EUROPE NON-STEROIDAL ANTI-INFLAMMATORY DRUGS MARKET SIZE, BY RELEASE TYPE, 2018-2032 (USD MILLION)
TABLE 269. EUROPE NON-STEROIDAL ANTI-INFLAMMATORY DRUGS MARKET SIZE, BY MODIFIED-RELEASE, 2018-2032 (USD MILLION)
TABLE 270. EUROPE NON-STEROIDAL ANTI-INFLAMMATORY DRUGS MARKET SIZE, BY PATIENT GROUP, 2018-2032 (USD MILLION)
T

Companies Mentioned

The key companies profiled in this Non-steroidal Anti-inflammatory Drugs market report include:
  • Abbvie, Inc
  • Algen Healthcare Ltd.
  • Allegiant Health
  • Amgen Inc.
  • Amneal Pharmaceuticals LLC
  • Arcutis Biotherapeutics, Inc.
  • Astellas Pharma Inc.
  • AstraZeneca PLC
  • BASF SE
  • Bayer AG
  • Boehringer Ingelheim GmbH
  • Bristol-Myers Squibb Company
  • Clearsynth Labs Limited
  • Daiichi Sankyo Company, Limited
  • Dr. Reddy’s Laboratories Ltd.
  • Eisai Co., Ltd.
  • Eli Lilly and Company
  • EMS S.A.
  • Genentech, Inc. by F. Hoffmann-La Roche AG
  • Gilead Sciences, Inc.
  • GlaxoSmithKline PLC
  • Hikma Pharmaceuticals PLC
  • Incyte Corporation
  • Johnson & Johnson Services, Inc.
  • Merck KGaA
  • Novartis AG
  • Pfizer Inc.
  • Pharbest Pharmaceuticals, Inc.
  • Sandoz International GmbH
  • Sanofi S.A.
  • Spectrum Chemical Mfg. Corp.
  • Sun Pharmaceutical Industries Ltd.
  • Takeda Pharmaceutical Co. Ltd.
  • Teikoku Seiyaku Co., Ltd.
  • Teva Pharmaceutical Industries Ltd.
  • Verona Pharma plc
  • Viatris Inc.

Table Information

Report AttributeDetails
No. of Pages190
PublishedJanuary 2026
Forecast Period2026 - 2032
Estimated Market Value ( USD ) in 2026 $ 26.22 Billion
Forecasted Market Value ( USD ) by 2032 $ 38.81 Billion
Compound Annual Growth Rate6.7%
Regions CoveredGlobal
No. of Companies Mentioned38

Related Topics

Related Reports

Non-steroidal Anti-Inflammatory Drugs (NSAIDs) Market Report and Forecast 2025-2034 - Product Image

Non-steroidal Anti-Inflammatory Drugs (NSAIDs) Market Report and Forecast 2025-2034

  • Report
  • 350 Pages
  • Global
From
Non-Steroidal Anti-inflammatory Drugs Market Report 2025 - Product Image

Non-Steroidal Anti-inflammatory Drugs Market Report 2025

  • Report
  • 250 Pages
  • Global
From
Non-steroidal Anti-inflammatory Drug Global Market Insights 2025, Analysis and Forecast to 2030, by Market Participants, Regions, Technology, Application, Product Type - Product Image

Non-steroidal Anti-inflammatory Drug Global Market Insights 2025, Analysis and Forecast to 2030, by Market Participants, Regions, Technology, Application, Product Type

  • Report
  • 101 Pages
  • Global
From
Dermatological Non-Steroidal Anti-Inflammatory Drugs Market - Global Forecast 2025-2030 - Product Image

Dermatological Non-Steroidal Anti-Inflammatory Drugs Market - Global Forecast 2025-2030

  • Report
  • 192 Pages
  • Global
From
Dental Anti-inflammatory Drug Market Report: Trends, Forecast and Competitive Analysis to 2031 - Product Image

Dental Anti-inflammatory Drug Market Report: Trends, Forecast and Competitive Analysis to 2031

  • Report
  • 150 Pages
  • Global
From

About the NSAID Market

Over the Counter (OTC) Non-Steroidal Anti-Inflammatory Drugs (NSAIDs) are a class of medications used to reduce inflammation and pain. They are available without a prescription and are used to treat a variety of conditions, including headaches, muscle aches, arthritis, and menstrual cramps. NSAIDs work by blocking the production of certain chemicals in the body that cause inflammation and pain. Common OTC NSAIDs include ibuprofen, naproxen, and aspirin. NSAIDs are generally safe and effective when taken as directed. However, they can cause side effects, such as stomach upset, nausea, and dizziness. People with certain medical conditions, such as kidney or liver disease, should not take NSAIDs without consulting their doctor. Companies in the OTC NSAID market include Bayer, Pfizer, GlaxoSmithKline, Novartis, and Johnson & Johnson. Show Less Read more

Copyright © 2002-2026 Research and Markets. All Rights Reserved.